These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 35057893)
1. Targeted Delivery of Glypican 3 (GPC3) Antibody-Modified MicroRNA (miR let-7b-5p) Polymer Nanoparticles to Sorafenib-Resistant Hepatsocellular Carcinoma Cells. Zhou S; Ma Y; Liu X; Yu P; Huang N; Song L; Xu R; Huo Z; Zhu T; Tang X J Biomed Nanotechnol; 2021 Apr; 17(4):677-690. PubMed ID: 35057893 [TBL] [Abstract][Full Text] [Related]
2. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268 [TBL] [Abstract][Full Text] [Related]
3. MiR-375 attenuates sorafenib resistance of hepatocellular carcinoma cells by inhibiting cell autophagy. Wang D; Yang J Acta Biochim Pol; 2023 Apr; 70(2):239-246. PubMed ID: 37068178 [TBL] [Abstract][Full Text] [Related]
4. The lncRNA lnc-TSI antagonizes sorafenib resistance in hepatocellular carcinoma via downregulating miR-4726-5p expression and upregulating KCNMA1 expression. Chen F; Jiang J; Liu D; Li H; Dong L; Song Y; Zhang Y; Wang J; Qin Y; Zhao G J Mol Histol; 2024 Feb; 55(1):83-96. PubMed ID: 38165571 [TBL] [Abstract][Full Text] [Related]
5. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma. Sui C; Dong Z; Yang C; Zhang M; Dai B; Geng L; Lu J; Yang J; Xu M J Cell Mol Med; 2019 Sep; 23(9):6024-6033. PubMed ID: 31210410 [TBL] [Abstract][Full Text] [Related]
6. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2. Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714 [TBL] [Abstract][Full Text] [Related]
7. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma. Kumar M; Kaur R; Kanthaje S; Dhiman RK; Chakraborti A J Cancer Res Clin Oncol; 2023 Aug; 149(9):5823-5839. PubMed ID: 36583742 [TBL] [Abstract][Full Text] [Related]
8. Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma. Li H; Gai L; Wu Z; Li F Mol Biol Rep; 2022 Apr; 49(4):3015-3024. PubMed ID: 35013864 [TBL] [Abstract][Full Text] [Related]
9. The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma. Zhang Z; Tan X; Luo J; Yao H; Si Z; Tong JS Cell Death Dis; 2020 Oct; 11(10):902. PubMed ID: 33097691 [TBL] [Abstract][Full Text] [Related]
10. MiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinoma. Liu L; Lu L; Zheng A; Xie J; Xue Q; Wang F; Wang X; Zhou H; Tong X; Li Y; Zhu X; Wu G Oncotarget; 2017 Feb; 8(8):13666-13677. PubMed ID: 28099144 [TBL] [Abstract][Full Text] [Related]
11. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148 [TBL] [Abstract][Full Text] [Related]
12. SNHG16 as the miRNA let-7b-5p sponge facilitates the G2/M and epithelial-mesenchymal transition by regulating CDC25B and HMGA2 expression in hepatocellular carcinoma. Li S; Peng F; Ning Y; Jiang P; Peng J; Ding X; Zhang J; Jiang T; Xiang S J Cell Biochem; 2020 Mar; 121(3):2543-2558. PubMed ID: 31696971 [TBL] [Abstract][Full Text] [Related]
13. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription. Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282 [TBL] [Abstract][Full Text] [Related]
14. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740 [TBL] [Abstract][Full Text] [Related]
15. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles. Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460 [TBL] [Abstract][Full Text] [Related]
16. Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis. Al-Noshokaty TM; Mesbah NM; Abo-Elmatty DM; Abulsoud AI; Abdel-Hamed AR Life Sci; 2022 Aug; 303():120675. PubMed ID: 35640776 [TBL] [Abstract][Full Text] [Related]
17. Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway. Li WF; Dai H; Ou Q; Zuo GQ; Liu CA Tumour Biol; 2016 May; 37(5):5885-95. PubMed ID: 26589417 [TBL] [Abstract][Full Text] [Related]
18. Nanoparticles Loaded with GSK1059615 Combined with Sorafenib Inhibited Programmed Cell Death 1 Ligand 1 Expression by Negatively Regulating the PI3K/Akt/NF- Zhou S; Ma Y; Xu R; Tang X J Biomed Nanotechnol; 2022 Mar; 18(3):693-704. PubMed ID: 35715918 [TBL] [Abstract][Full Text] [Related]
19. miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line. Kaur R; Kanthaje S; Taneja S; Dhiman RK; Chakraborti A Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011286 [TBL] [Abstract][Full Text] [Related]
20. The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance. Gong J; He L; Ma J; Zhang J; Wang L; Wang J J BUON; 2017; 22(2):454-461. PubMed ID: 28534369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]